Piscataway, New Jersey, December 5, 2022 /PRNewswire/ — Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) today announced U.S. approval of a generic version of Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL.[1]Aucta plans to commercialize this product in early 2023.
Annual US sales of oxcarbazepine oral suspension are $74 million in total over a period of 12 months October 2022 According to data available from IQVIATMs.
Lee Shou Fengsaid the CEO of Aucta Pharmaceuticals.nd Last 10 days. This is the beginning of our growth phase, with more products running through our pipeline over the next three years. “
See full prescribing information available at www.dailymed.nlm.nih.gov.
About Okta Pharmaceuticals
Aucta Pharmaceuticals, Inc. is a research and technology-based pharmaceutical company focused on the development and commercialization of niche generic and branded specialty products. The company’s corporate strategy is to focus on proven molecules and, through innovation, create new, scientifically low-risk therapies that meet unmet medical needs. Its specialty divisions focus on CNS, ophthalmology, respiratory and other specialties. For more information, please visit www.auctapharma.com.
[1] Trileptal® is a registered trademark of Novartis Pharmaceuticals Corporation.
Source: Oakta Pharmaceuticals, Inc.
